Published in Int J Endocrinol on July 27, 2015
Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA (2006) 22.71
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med (1994) 8.39
A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer (1998) 8.03
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab (2006) 5.78
BRAF mutation in thyroid cancer. Endocr Relat Cancer (2005) 5.65
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol (2009) 3.02
Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid (2004) 2.83
Thyroid cancer mortality and incidence: a global overview. Int J Cancer (2014) 2.63
Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol (2008) 2.58
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab (2003) 2.44
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J (2008) 2.06
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res (2012) 2.02
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab (2007) 1.93
Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol (2007) 1.92
BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol (2012) 1.90
Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A (2007) 1.84
The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg (2005) 1.67
Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases. Eur Arch Otorhinolaryngol (2011) 1.66
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer (2006) 1.56
Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene (2011) 1.48
The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res (2009) 1.48
The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol (2010) 1.37
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer (2006) 1.33
Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res (2007) 1.29
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist (2011) 1.27
BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg (2012) 1.23
Time trends of incidence rates of thyroid cancer in Israel: what might explain the sharp increase. Thyroid (2006) 1.20
KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One (2012) 1.14
Preoperative staging of thyroid papillary carcinoma with ultrasonography. Eur J Radiol (1998) 1.09
Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab (2012) 1.09
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid (2013) 1.05
Molecular analysis of thyroid tumors. Mod Pathol (2011) 1.04
Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol (2011) 0.98
Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension. Ann Surg Oncol (2009) 0.98
Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis. Genes Chromosomes Cancer (2012) 0.97
Thyroid cancer: molecular aspects and new therapeutic strategies. J Thyroid Res (2012) 0.94
Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery (2012) 0.94
Time trends and geographic variations for thyroid cancer in New Caledonia, a very high incidence area (1985-1999). Eur J Cancer Prev (2007) 0.94
BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine (2012) 0.89
BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR. Ann Surg Oncol (2012) 0.89
[Trend of incidence and mortality on thyroid cancer in China during 2003 - 2007]. Zhonghua Liu Xing Bing Xue Za Zhi (2012) 0.89
Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. Sci Rep (2015) 0.87
Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J Clin Endocrinol Metab (2013) 0.87
Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing. J Surg Res (2012) 0.86
Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. Endocr J (2011) 0.84
Is the type of dissection in lateral neck metastasis for differentiated thyroid carcinoma important? Otolaryngol Head Neck Surg (2007) 0.83
Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma. World J Surg Oncol (2013) 0.82
Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland China. Dis Markers (2014) 0.79
BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China. World J Surg Oncol (2012) 0.79